Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tang, Bo ^a   Li, Yang ^a   Qi, Guangying ^a   Yuan, Shengguang ^a   Wang, Zhenran ^a   Yu, Shuiping ^a   Li, Bo ^a   He, Songqing ^a  

^a GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENETIC MARKER; TUMOR MARKER;

DNA METHYLATION; EPIDEMIOLOGY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HUMAN; INCIDENCE; MALE; META ANALYSIS; MOLECULAR GENETICS; MORTALITY; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PROMOTER REGION; RISK FACTOR; SURVIVAL RATE;

BASE SEQUENCE; BIOMARKERS, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; RISK FACTORS; SURVIVAL RATE;

EID: 84941006304     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13563     Document Type: Article

References (50)

1. Neureiter, D., Jager, T., Ocker, M. & Kiesslich, T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol 20, 7830-7848, doi: 10.3748/wjg.v20.i24.7830 (2014).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 62, 10-29, doi: 10.3322/caac.20138 (2012).
3. Schnelldorfer, T. et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Annals of surgery 247, 456-462, doi: 10.1097/SLA.0b013e3181613142 (2008).
4. Rossi, M. L., Rehman, A. A. & Gondi, C. S. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 20, 11142-11159, doi: 10.3748/wjg.v20.i32.11142 (2014).
5. Vogelstein, B. & Kinzler, K. W. Cancer genes and the pathways they control. Nat Med 10, 789-799, doi: 10.1038/nm1087 (2004).
6. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554, doi: 0092-8674(88)90571-5 (1988).
7. Koh, Y. X., Chok, A. Y., Zheng, H. L., Tan, C. S. & Goh, B. K. A systematic review and meta-analysis of the clinicopathologic characteristics of cystic versus solid pancreatic neuroendocrine neoplasms. Surgery 156, 83-96 e82, doi: S0039-6060(14)00119-6 (2014).
8. Singhi, A. D. et al. Cystic pancreatic neuroendocrine tumors: a clinicopathologic study. Am J Surg Pathol 36, 1666-1673, doi: 10.1097/PAS.0b013e31826a0048 (2012).
9. Boninsegna, L. et al. Pancreatic cystic endocrine tumors: a different morphological entity associated with a less aggressive behavior. Neuroendocrinology 92, 246-251, doi: 000318771 (2010).
10. Ahrendt, S. A., Komorowski, R. A., Demeure, M. J., Wilson, S. D. & Pitt, H. A. Cystic pancreatic neuroendocrine tumors: is preoperative diagnosis possible? J Gastrointest Surg 6, 66-74, doi: S1091255× 01000208 (2002).
11. Simon, B. & Lubomierski, N. Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis. Ann N Y Acad Sci 1014, 284-299 (2004).
12. Dauksa, A. et al. Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. PLoS One 7, e37509 (2012).
13. Li, G., Ji, Y., Liu, C., Li, J. & Zhou, Y. Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in pancreatic carcinoma. Mol Med Rep 5, 1106-1110 (2012).
14. Tan, S. H. et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 18, 1225-1230 (2007).
15. Jiao, L. et al. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 34, 55-62 (2007).
16. Matsubayashi, H. et al. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res 66, 1208-1217 (2006).
17. Peng, D. F. et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27, 1160-1168 (2006).
18. Liu, L. et al. Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis. Mod Pathol 18, 1632-1640 (2005).
19. Chan, A. O. et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 22, 924-934 (2003).
20. Yan, L. et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 128, 2124-2130 (2005).
21. Klump, B. et al. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 88, 217-222 (2003).
22. House, M. G. et al. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Annals of surgery 238, 423-431 discussion 431-422 (2003).
23. Fukushima, N. et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160, 1573-1581 (2002).
24. Ohtsubo, K. et al. Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma: immunohistochemical and genetic findings compared with clinicopathological parameters. J Gastroenterol 38, 663-671, doi: 10.1007/s00535-003-1119-6 (2003).
25. Fukushima, N. et al. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther 2, 78-83, doi: 183 (2003).
26. Gerdes, B. et al. p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. Surgery 129, 490-497 (2001).
27. Zamboni, G., Hirabayashi, K., Castelli, P. & Lennon, A. M. Precancerous lesions of the pancreas. Best practice & research. Clinical gastroenterology 27, 299-322, doi: 10.1016/j.bpg.2013.04.001 (2013).
28. Liu, S. L., Chen, G., Zhao, Y. P., Wu, W. M. & Zhang, T. P. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis. Hepatobiliary Pancreat Dis Int 12, 458-464 (2013).
29. Parikh, R., Mathai, A., Parikh, S., Chandra Sekhar, G. & Thomas, R. Understanding and using sensitivity, specificity and predictive values. Indian J Ophthalmol 56, 45-50 (2008).
30. Gerdes, B. et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Annals of surgery 235, 51-59 (2002).
31. Blackford, A. et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 69, 3681-3688, doi: 0008-5472.CAN-09-0015 (2009).
32. Stathis, A. & Moore, M. J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7, 163-172, doi: nrclinonc.2009.236 (2010).
33. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806, doi: 1164368 (2008).
34. Iacobuzio-Donahue, C. A. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut 61, 1085-1094, doi: gut.2010.236026 (2012).
35. Gerdes, B. et al. Tumor-suppressing pathways in cystic pancreatic tumors. Pancreas 26, 42-48, doi: 00006676-200301000-00008 (2003).
36. Gerdes, B. et al. Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients? Pancreas 21, 369-375 (2000).
37. van Kampen, J. G. et al. Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40, 656-664, doi: S0305-7372(13)00265-X (2014).
38. El-Maarri, O., Herbiniaux, U., Walter, J. & Oldenburg, J. A rapid, quantitative, non-radioactive bisulfite-SNuPE-IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res 30, e25 (2002).
39. El-Maarri, O. SIRPH analysis: SNuPE with IP-RP-HPLC for quantitative measurements of DNA methylation at specific CpG sites. Methods Mol Biol 287, 195-205, doi: 1-59259-828-5:195 (2004).
40. Teich, N. & Mossner, J. Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis 22, 235-238, doi: 82794 (2004).
41. Moore, P. S. et al. Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84, 253-262, doi: 10.1054/bjoc.2000.1567 (2001).
42. Zhao, S., Venkatasubbarao, K., Li, S. & Freeman, J. W. Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res 63, 2624-2630 (2003).
43. von Burstin, J. et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 137, 361-371, 371 e361-365, doi: S0016-5085(09)00545-9 (2009).
44. Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745, doi: S0092-8674(07)00190-0 (2007).
45. Baumgart, S. et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 142, 388-398 e381-387, doi: S0016-5085(11)01514-9 (2012).
46. Moriyama, T. et al. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8, 1067-1074, doi: 1535-7163.MCT-08-0592 (2009).
47. Dillhoff, M., Liu, J., Frankel, W., Croce, C. & Bloomston, M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg 12, 2171-2176, doi: 10.1007/s11605-008-0584-x (2008).
48. Lanlan Shen, R. A. W. Methods of DNA methylation analysis. Curr Opin Nutr Metab Care, 10, 576-581 doi: 10.1097/MCO.0b013e3282bf6f43 (2007).
49. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935, doi: 1170116 (2009).
50. Huang, Y. et al. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 5, e8888, doi: 10.1371/journal. pone.0008888 (2010).